Bilateral atrial appendage thrombosis in light chain cardiac amyloidosis: a case report
Abstract
Light chain cardiac amyloidosis (AL-CA) is a severe and progressively infiltrative disease caused by the deposition of misfolded monoclonal immunoglobulin light chains in the myocardial extracellular space. It is associated with poor prognosis and typically presents as diastolic heart failure, arrhythmias, and atrial appendage thrombosis. We report a case of light chain cardiac amyloidosis with bilateral atrial appendage thrombosis. The patient died from refractory heart failure four months after diagnosis.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.